{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-014951","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.151034+00:00","generated_at":"2026-05-15T07:52:30.316302+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Calidi Biotherapeutics director Allan Camaisa to step down at 2026 annual meeting; Board reduced to 5","bullets":["Director Allan J. Camaisa will not stand for re-election; term expires at 2026 annual meeting; no disagreement with company.","Board reduced from six to five directors effective at the 2026 annual meeting.","Scott Leftwich appointed to Audit Committee effective April 1, 2026.","Camaisa's departure is not due to any disagreement with company operations or policies."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-014951","json":"https://secwatch.observer/filing/0001493152-26-014951.json","markdown":"https://secwatch.observer/filing/0001493152-26-014951.md","text":"https://secwatch.observer/filing/0001493152-26-014951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226014951/0001493152-26-014951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226014951/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:52:30.316302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}